My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
VRCA nasdaq
United States
Verrica Pharmaceuticals

Verrica Pharmaceuticals Stock Analysis & Ratings

Verrica Pharmaceuticals Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Verrica Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

VRCA

VRCA Stock Stats

Previous Close$12.39
Open$0
Bid12.3 x 1
Ask13.47 x 500
Today’s Range$0 - $0
52-Week Range$7.05 - $18.42
Volume1.00
Average Volume111.54K
Market Cap$340.91M
Beta2.12
P/E Ratio-9.5
EPS-1.41
Earnings DateNov 10, 2021

Company Description

Verrica Pharmaceuticals

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Sector
Healthcare
Industry
Biotechnology
CEO
Ted White
Employees
29
ISIN
US92511W1080
Address
10 North High Street, West Chester, PA, 19380, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

VRCA FAQ

What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $7.05 and its highest was $18.42 in the past 12 months.
    What is Verrica Pharmaceuticals’s market cap?
    Verrica Pharmaceuticals’s market cap is $340.91M.
      What is Verrica Pharmaceuticals’s price target?
      The average price target for Verrica Pharmaceuticals is $18.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 51.74% Increase from the current price of $12.39.
        What do analysts say about Verrica Pharmaceuticals?
        Verrica Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Verrica Pharmaceuticals’s upcoming earnings report date?
          Verrica Pharmaceuticals’s upcoming earnings report date is Nov 10, 2021 which is in 21 days.
            How were Verrica Pharmaceuticals’s earnings last quarter?
            Verrica Pharmaceuticals released its earnings results on Aug 10, 2021. The company reported -$0.428 earnings per share for the quarter, missing the consensus estimate of -$0.414 by -$0.014.
              Is Verrica Pharmaceuticals overvalued?
              According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
                Does Verrica Pharmaceuticals pay dividends?
                Verrica Pharmaceuticals does not currently pay dividends.
                What is Verrica Pharmaceuticals’s EPS estimate?
                Verrica Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Verrica Pharmaceuticals have?
                Verrica Pharmaceuticals has 27,510,000 shares outstanding.
                  What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
                  Verrica Pharmaceuticals reported an EPS of -$0.428 in its last earnings report, missing expectations of -$0.414. Following the earnings report the stock price went down -1.571%.
                    Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
                    Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 41M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis